Croma-Pharma Expands Successful Mask Range With Face Masks for Different Areas of Application
21.10.2021 12:38:00 EEST | Business Wire | Press release
Croma-Pharma (Croma) announced today the expansion of its successful mask portfolio. The carefully selected ingredients of each formulation, as well as the sheet material, are tailored to specific application areas and skin needs. The products have a pleasant texture and are suitable for all skin types.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211021005468/en/
@Croma (Photo: Business Wire)
The right mask for every need
The Croma mask portfolio offers two full face masks, as well as masks for specific areas of the face including the eyes, lips, and laugh lines.
Calming face mask with aloe vera, green tea and rosehip oil
The Croma calming face mask contains ingredients known for their antioxidant and soothing effects, as well as skin-regenerating properties. It replenishes the skin with vitamins and helps to protect against harmful environmental influences. Regular use may help to strengthen the skin barrier and provides optimal care for the skin. The material consists of 80 percent green tea fibers and 20 percent cupro - so not only the serum per se works to achieve the desired effect, but also the mask material itself.
Key ingredients: hyaluronic acid, rosehip oil, green tea leaf extract, aloe vera juice
Recommended retail price: EUR 59,-
Rejuvenating face mask with hyaluronic acid
This hyaluronic acid mask has long been considered to be one of Croma Pharma Skincare's most popular products. The incorporated ingredients refresh dehydrated skin, alleviate visible dryness and help to improve the skin’s elasticity. In addition to its pleasant cooling effect, the formulation may help to smooth small wrinkles and ensures a radiant complexion. Regular use can help to fight the signs of skin aging and maintain a youthful appearance.
Key ingredients: hyaluronic acid, imperata cylindrica root extract, irish moss extract
Recommended retail price: EUR 59,-
Organic cellulose masks for special facial areas
Energizing eye mask with hyaluronic acid, kiwi and cucumber extract
Croma energizing eye mask provides an instant boost of hydration. The mask is packed with soothing ingredients which sustainably improve the skin barrier function and skin elasticity. The fermented extracts nourish the skin with valuable postbiotics. The eye mask contains powerful antioxidants – including vitamin C – and helps to moisturize and reduce signs of fatigue, while providing an extra energy kick for a fresh and energized appearance.
Key ingredients: hyaluronic acid, kiwi fruit ferment, cucumber extract
Recommended retail price: EUR 55,-
Regenerating lip mask with hyaluronic acid, aloe vera and berry ferment
The regenerating lip mask infused with hyaluronic acid, aloe vera and berry ferment that deeply moisturize the delicate lip area while providing a cooling and regenerating effect. The ingredients soften and plump the lips.
Key ingredients: hyaluronic acid, aloe vera, berry ferment
Recommended retail price: EUR 55,-
Firming laugh line mask with hyaluronic acid and pomegranate extract
Croma firming mask for laugh lines is enriched with hyaluronic acid to intensely hydrate and soothe the skin of the nasolabial folds. The carefully selected ingredients include Palmitoyl hexapeptide, a biomimetic peptide that gives a firming effect and can smooth the appearance of wrinkles. Pomegranate ferment extract, a potent antioxidant, may increase skin collagen.
Key ingredients: hyaluronic acid, palmitoyl hexapeptide-12, pomegranate fermented extract
Recommended retail price: EUR 55,-
Croma expert tip - the right application
Croma Expert Tip by Dr. Monika Sulovsky, Yuvell® Committed to Beauty: “A moisturizing mask is a freshness boost for any skin type and can easily be applied in the morning or evening.
- Step 1: A face mask is always applied to a cleansed face and is used before serums or creams.
- Step 2: The mask should be left on for 15 minutes.
- Step 3: Finally, remove the mask and gently massage the excess serum into the skin.”
“Our Croma face masks have been very popular for a long time. This was also a welcome occasion for us to expand the portfolio in order to be able to offer our customers a comprehensive beauty treatment at home", explains Andreas Prinz, the Managing Director of Croma-Pharma.
Availability
The Croma masks are available via www.cromaskincareshop.com and selected partners.
About Croma
Founded in 1976, Croma-Pharma GmbH (Croma) is an Austrian family-owned company that specializes in the industrial production of hyaluronic acid syringes for the fields of medical aesthetics, ophthalmology and orthopaedics. Croma currently runs 12 international sales companies and distributes its products in more than 70 countries. Within its global sales network, Croma focuses its own branded products on minimally invasive aesthetic medicine. In addition to a broad range of HA fillers produced on site, Croma also markets PDO lifting threads, a Platelet Rich Plasma (PRP) system and high-quality skincare technologies in its core strategic markets.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211021005468/en/
Contact information
CROMA-PHARMA GmbH
Stefanie Höhn
Global Director Communications
Cromazeile 2
A-2100 Leobendorf
Tel.: +43 676 846868 190
Mail: stefanie.hoehn@croma.at
Web: www.croma.at
CROMA-PHARMA GmbH
Simone Turek
External Communications Manager
Cromazeile 2
A-2100 Leobendorf
Tel.: +43 676 846868 654
Mail: simone.turek@croma.at
Web: www.croma.at
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Presents New Data on ALYFTREK ® at European Cystic Fibrosis Conference5.6.2026 19:00:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating the long-term safety and efficacy profile of the medicine. The data, presented at the European Cystic Fibrosis Conference, show children ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including those who are homozygous for the F508del mutation (F/F) and those who have F508del/minimal function mutations (F/MF)on ALYFTREK had further improvement in CFTR function from a TRIKAFTA ® baseline as measured by sweat chloride (SwCl), with 65% having achieved SwCl <30 mmol/L after treatment with ALYFTREK. Vertex also presented Phase 3 data of children ages 1 to <2 with TRIKAF
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 14:00:00 EEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 13:41:00 EEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.6.2026 13:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to seventeen newly hired non-executive employees. The equity awards were granted on June 1, 2026 and consisted of options to purchase an aggregate of 157,000 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 74,700 shares. The options have an exercise price per share equal to $14.19, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restrict
Renewable Electricity, Soft Wheat Flour From Regenerative Agriculture, Initiatives to Support Local Communities: Barilla Shares These and Other Projects in “Stories of Sustainability.”5.6.2026 11:00:00 EEST | Press release
A slimmer Tagliatelle pack that saves 150 tons of cardboard and cuts transport-related CO₂ emissions by 20%1; ready-made sauce jars made with around 65% recycled glass; the progressive scaling of regenerative agriculture practices across Barilla’s value chain and initiatives supporting inclusion and equal opportunities across the Group’s production sites and communities. These are just some of the “sustainability” stories the Barilla Group is sharing on World Environment Day with the publication of its 2025 Sustainability Report. The report comes just after Barilla was named the world’s most reputable company in the food sector for the third year running and, for the first time, ranked among the global top 10 in the Global RepTrak 100 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603162436/en/ “The future of the planet will increasingly depend on our ability to spread culture and education,” says Paolo Barilla, Vic
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom